Table 1 Enrichment of the MPS in multiple prostate cancer patient cohorts

Taylor prostate 3

Metastatic status

287

4.38E-109

7.2

10

Varambally prostate

Metastatic status

238

6.14E-73

5.4

10

LaTulippe prostate

Metastatic status

107

2.40E-24

3.8

10

Yu prostate

Metastatic status

103

4.74E-22

3.6

10

Chandran prostate

Metastatic status

121

8.59E-14

2.3

10

Vanaja prostate

Metastatic status

128

2.44E-13

2.2

10

Lapointe prostate

Metastatic status

99

3.38E-13

2.5

10

Holzbeierlein prostate

Metastatic status

50

7.67E-08

2.5

10

Tamura prostate

Metastatic status

93

9.64E-08

1.9

10

Ramaswamy multi-cancer

Metastatic status

74

2.42E-06

1.9

10

Magee prostate

Metastatic status

21

0.003

2.1

5

Ramaswamy multi-cancer 2

Metastatic status

35

0.003

1.7

5

Glinsky prostate

Recurrence status at 3 years

93

2.94E-08

2

10

Recurrence status at 5 years

90

2.32E-07

1.9

10

Nakagawa prostate

Recurrence status at 1 year

7

3.42E-04

7.5

5

Recurrence status at 3 years

12

7.50E-06

7.4

10

Recurrence status at 5 years

12

7.50E-06

7.4

10

Survival status at 3 years

12

7.50E-06

7.4

10

Survival status at 5 years

9

3.52E-06

12

5

Nakagawa prostate 2

Recurrence status at 1 year

7

8.37E-04

6.4

5

Recurrence status at 3 years

12

3.94E-05

6

10

Recurrence status at 5 years

7

8.37E-04

6.4

5

Survival status at 3 years

13

5.95E-06

7

10

Survival status at 5 years

10

0.001

4.3

10

Setlur prostate

Survival status at 1 year

46

2.28E-04

1.9

10

Survival status at 3 years

46

8.94E-14

4.4

5

Survival status at 5 years

50

1.84E-16

4.9

5

Taylor prostate 3

Recurrence status at 3 years

84

4.31E-14

2.8

5

Recurrence status at 5 years

48

8.95E-27

9.1

1

Barwick prostate

Recurrence status at 5 years

7

3.42E-04

7.5

5